Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
METAPANC
2023-503558-10-00Phase 3Authorised
- Sponsor
- Universitätsmedizin Göttingen
- Start
- Oct 2023
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of oxaliplatin, fluorouracil, irinotecan and folinic acid in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Universitätsmedizin Göttingen. Primary endpoint: Overall survival. Planned start Oct 2023; status: authorised.
02
Drugs
oxaliplatinfluorouracilirinotecanfolinic acid
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2023-503558-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503558-10-00.